Business brief
Industrial Mega-Deals and Licensing Battles
Schneider Electric clinches PTC in a $22.6B industrial buyout as Qualcomm and Arm clash over chip royalties in Delaware.
Business
Schneider is paying $22.6B to lock down industrial software — uniting digital engineering blueprints with factory equipment before rivals can close the loop.
BackgroundIndustrial automation conglomerates link electrical hardware with factory software to design and manage automated production lines. Schneider acquired British engineering software firm Aveva in 2023 to expand beyond physical power distribution into cloud-based industrial controls.
- Schneider will pay a 42.3% cash premium for Boston-based PTC, financing the acquisition through balance-sheet cash and freshly drawn syndicated debt facilities.
- The combination targets €250M in annual run-rate cost synergies and €800M in long-term cross-selling revenue across connected factory platforms.
- Antitrust regulators across Washington and Brussels will review the transaction, with the companies targeting closing in the third quarter of 2027.
Business
Qualcomm is fighting to halt billions in Arm licensing royalties — a courtroom clash that threatens to fracture mobile chip architecture economics.
BackgroundArm licenses fundamental semiconductor instruction sets that allow companies like Qualcomm and Apple to design microprocessors for smartphones and PCs. Qualcomm's 2021 purchase of startup Nuvia triggered years of acrimony over whether custom CPU architectures require higher royalty rates.
- Qualcomm claims Arm deliberately withheld core verification tools and improperly leaked contract cancellation notices that disrupted critical negotiations with Meta.
- Arm filed countersuits alleging Qualcomm violated non-disclosure pacts by leaking proprietary material to competition regulators investigating chip licensing fees.
- A companion bench trial will evaluate whether Arm negotiated in bad faith over Qualcomm's existing architectural agreements running through 2033.
Business
Paramount Skydance recruited Mattel's chief executive to shoulder operational downsizing — clearing executive bandwidth for studio expansion while winding down legacy cable networks.
BackgroundLegacy Hollywood studios are battling falling cable television subscriber fees alongside mounting streaming losses against deep-pocketed tech giants. Paramount Skydance agreed to acquire Warner Bros. Discovery to assemble theatrical production, studio lots, and combined streaming libraries.
- Kreiz will manage linear cable networks, production lots, and the eventual technical migration combining Paramount+ with Warner's Max service.
- David Ellison stays executive chairman and co-CEO, focusing on theatrical strategy, long-term corporate finance, and studio artificial intelligence tools.
- The merger cleared its final state hurdle after resolving an antitrust lawsuit with 12 state attorneys general by guaranteeing $1.5B in regional film production.
Business
CSL paid $355M upfront for Alentis's clinical antibody — buying an unproven fibrosis drug to restock its specialty pipeline before legacy patents expire.
BackgroundBiopharmaceutical developers seek targeted rare-disease therapies to shield cash flows against impending patent cliffs on older blockbuster treatments. Claudin-1 is an overexpressed structural protein on cell surfaces that drives severe organ tissue scarring and chronic fibrosis.
- CSL will pay $355M upfront and up to $1.2B in contingent clinical, regulatory, and commercial milestone payments as drug trials progress.
- CSL will finance global Phase 2 and Phase 3 development trials in full while keeping 55% of all worldwide net commercial profits.
- The partnership fills CSL's mid-stage specialty pipeline following corporate restructuring aimed at trimming lower-margin plasma collection units.
Business
Business
Business
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
